Teva Pharmaceutical Industries Limited (TEVA) Provides Update on Generic Evista(R) Litigation

9/24/2009 9:51:03 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA’s Orange Book for Eli Lilly’s Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva’s abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Teva Pharmaceutical Industries Limited

• Biotech/Pharma - Legal

• Biotech/Pharma - Legal (World)